MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Size: px
Start display at page:

Download "MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER"

Transcription

1 MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release draft Based on MedDRA version 7.1 ICH-Endorsed Guide for MedDRA Users on Data Output 18 November 2004

2 Copyright ICH Secretariat (c/o IFPMA) Copying is permitted, with reference to source, but material in this publication may not be used in any documentation or electronic media which is offered for sale, without the prior permission of the copyright owner. IFPMA 30 rue de St- Jean P.O. Box Geneva 13 Switzerland Tel: +41 (22) Fax: +41 (22) ii

3 Table of Contents 1 INTRODUCTION OBJECTIVE APPLICATIONS OF MEDDRA BACKGROUND SCOPE GENERAL PRINCIPLES QUALITY OF SOURCE DATA QUALITY ASSURANCE OF THE PROCESS OF DATA RETRIEVAL AND PRESENTATION ORGANIZATION-SPECIFIC DATA CHARACTERISTICS IMPACT OF MEDDRA S CHARACTERISTICS ON DATA RETRIEVAL AND PRESENTATION GRANULARITY MULTI-AXIALITY SPECIAL SEARCH CATEGORIES STANDARDIZED MEDDRA QUERIES MEDDRA VERSIONING QUERIES and RETRIEVAL GENERAL PRINCIPLES: OVERALL PRESENTATION OF SAFETY PROFILES OVERVIEW BY PRIMARY SYSTEM ORGAN CLASS FOCUSED SEARCHES Appendices: CURRENT MEMBERS OF THE ICH POINTS TO CONSIDER WORKING GROUP: PAST MEMBERS/AFFILIATIONS OF THE ICH POINTS TO CONSIDER WORKING GROUP: iii

4 1 INTRODUCTION The Medical Dictionary for Regulatory Activities (MedDRA) 1 was designed for the specific use of sharing regulatory information for human medical products. However, unless consistency can be achieved in the selection of terms for reported symptoms, signs, and diseases, etc. or in the methods used to retrieve data for evaluation, the terminology will yield little improvement over the divergent practices of the past. The MedDRA terminology was developed as a medically validated medical terminology for utilization throughout the regulatory process 2. MedDRA has a large number of very specific terms called Lowest Level Terms (LLTs) in order to accurately capture the reporter s words (verbatim term). This large number of LLTs results in a correspondingly large number of Preferred Terms (PTs), a concept that is sometimes referred to as granularity and/or specificity. A highly granular terminology minimizes the need for interpretation at data entry. However, classification of data received is only one part of the data management process that attempts to retrieve, sort and present data in the most understandable and reproducible way for the benefit of drug development, pharmacovigilance and risk management. Therefore, the developers of the terminology designed a structure that facilitates data retrieval in the form of grouping terms called High Level Terms (HLT) and High Level Group Terms (HGLT), which group very specific terms used for coding into broader medical concepts. Moreover, MedDRA s feature of multiaxiality, in which PTs can be assigned to more than one SOC, allows flexibility in data retrieval via different routes. While these features of MedDRA allow a reasonable "first approach" to data retrieval, the complexity of MedDRA calls for guidance to optimize the results. The MedDRA Data Retrieval and Presentation: Points to Consider document is an ICH-endorsed guide for MedDRA users. It is designed to be updated based on MedDRA changes, and is a companion document to the MedDRA terminology. The principles described in this document are most effective when the user has followed the principles of the MedDRA Term Selection: Points to Consider document for data entry (i.e., coding). This document was developed and is maintained by a working group charged by the ICH Steering Committee. Members of the working group include regulatory and industry representatives of the European Union, Japan and the United States, as well as representatives from Canada, the MedDRA Maintenance and Support Services Organization (MSSO), and Japanese Maintenance Organization (JMO). (See Appendix 1 for working group members.) This document is intended to provide data retrieval and presentation options for either industry or regulatory purposes. The examples contained in this document are based on MedDRA version 7.1 and are intended to facilitate reader comprehension. 1 MedDRA refers to all sequential and translated versions of the terminology, which are maintained by either the Maintenance and Support Services Organization (MSSO) or the Japanese Maintenance Organization (JMO). 2 From MedDRA 7.1 Introductory Guide 1

5 The examples presented are not intended to imply regulatory requirements. This document reflects a broad range of experience. It is expected that as experience with data retrieval and presentation of MedDRA-encoded data increases, there will be additions and perhaps changes to this document. 1.1 Objective The objective of the MedDRA Data Retrieval and Presentation: Points to Consider document is to provide assistance and understanding of the implications that the various options for data retrieval have on the accuracy and consistency of the final output. For example, certain drugs and/or therapeutic areas might need a customized approach for data output. One should take into consideration the options for data input that are described in the MedDRA Term Selection: Points to Consider document or in company specific coding practices. For reproducibility and understanding, organizations are encouraged to document their data retrieval and output strategies, methods and quality assurance procedures in organization specific guidelines, which should be consistent with this document. 1.2 Applications of MedDRA To aggregate reported terms in medically meaningful groupings for the purpose of reviewing and/or analyzing safety data To facilitate identification of common data sets for evaluation of clinical and safety information To facilitate consistent retrieval of specific cases or medical conditions from a database To improve consistency in comparing and understanding safety signals and aggregated clinical data To facilitate electronic data interchange of clinical safety information To report adverse drug reaction/adverse event (ADR/AE) 3 terms via individual case safety reports To report ADR/AEs in tables, analyses, and line listings To identify frequency of medically similar ADR/AEs To capture and present product indications, investigations, medical history and social history data 1.3 Background This Points to Consider document has been prepared to help all MedDRA users begin on common ground, as the MedDRA terminology itself does not contain specific guidelines for its use. The document provides a framework to foster consistent use of MedDRA for data retrieval and presentation, with the goal of allowing medically meaningful review and analysis of clinical data. 2 For ADR/AE definitions, refer to ICH Guidelines and CIOMS publications. 2

6 The intent of this document is to describe the possibilities of MedDRA and to highlight the impact of the structure, rules and conventions of MedDRA on data output. It is written to address principles only. The examples and options for use that are provided are not intended to communicate specific regulatory reporting requirements or address database issues. As this document cannot address every situation, medical judgment should always be applied. This document is not a substitute for MedDRA training. It is considered essential that users have knowledge of the complexity and content of MedDRA. The reader should also refer to the MedDRA Introductory Guide and the MedDRA Term Selection: Points to Consider document. 1.4 Scope The principles described in this document apply to all data encoded with MedDRA. The focus is on aggregated data. This document does not address the use of MedDRA for: Single case reporting Labeling Medical evaluation Statistical methodology 2 GENERAL PRINCIPLES 2.1 Quality of Source Data High quality data output is dependent upon maintaining the quality of the information originally reported by using consistent and appropriate term selection. Organizations are encouraged to pursue continuous oversight of data quality. Data quality issues are also addressed in MedDRA Term Selection: Points to Consider. Special consideration should be given to the methodology used for the conversion of data from other terminologies into MedDRA. The manner in which data were converted might impact retrieval and presentation strategies. For example, when data are converted directly from legacy terms to MedDRA terms, the results typically reflect only the specificity of the previous terminology; there is no benefit gained from the greater specificity of MedDRA. Example: Reported term: Bowel ischaemia Legacy term: Gastrointestinal Disorder MedDRA term: Gastrointestinal disorder In contrast, data re-coded from the reported term to the MedDRA term retains the specificity of the reported term. 3

7 Example: Reported term: Bowel ischaemia Legacy term: Gastrointestinal Disorder MedDRA term: Bowel ischaemia It is important to clearly describe the data sets and to document the conversion process(es). Consequences for data retrieval Keep in mind that interpretation of the data output can be affected if the two methods described above are combined. For example, if legacy data have been converted directly from legacy terms to MedDRA terms and newly acquired data are coded in MedDRA, the difference in resulting specificities could be problematic. When designing a search strategy, it might be appropriate to look at the verbatim terms for data converted using the first conversion method because if the query is based on specific MedDRA terms, the cases previously coded to a nonspecific term might be overlooked. For example, if searching on bowel ischaemia, cases of bowel ischaemia that had been coded under the legacy term gastrointestinal disorder would be missed. Should there be a need to conduct a search requiring this level of detail, it might be necessary to review or re-code the source data. 2.2 Quality Assurance of the Process of Data Retrieval and Presentation Careful documentation of the coding conventions used for data entry is essential for understanding and reproducing results. Organizations are encouraged to document their data retrieval and presentation strategies, methods, and quality assurance procedures in organization specific guidelines, which should be consistent with this document. The MedDRA terminology is multi-axial and more complex than common terminologies previously used. Therefore, an individual with a medical background who is also trained in the use of MedDRA should review the data retrieval and presentation strategy. MedDRA is a standardized terminology and the assignment of terms across System Organ Classes (SOCs) is pre-determined within the terminology; therefore, users should not alter it in any way. If users believe that term(s) are inappropriately placed in the hierarchy, they should inform the MedDRA MSSO via the change request process. 2.3 Organization-Specific Data Characteristics Although MedDRA is intended to be a standardized terminology, there are variations in the way that implementation has been conducted. It is important to understand the organization-specific characteristics of both the data and the implementation strategies. Each organization should have access to a MedDRA specialist who can provide 4

8 expert advice on MedDRA and has knowledge of the following characteristics of the database: Database structure (i.e., how hierarchy is stored and used) Data storage (e.g., level of term, synonym/reported term) Data migration from other terminologies to MedDRA Coding practices over time Limitations/restrictions (e.g., inability to view secondary SOCs or retrieve cases by secondary assignments) Knowledge of term selection principles used by an organization for coding is also critical. The following term selection points (which are discussed in detail in MedDRA Term Selection: Points to Consider document) illustrate some of the factors to keep in mind when planning retrieval and presentation of data: Selecting more than one term when coding a medical condition increases counts of terms. Conversely, selecting a diagnosis term only (without also selecting terms for signs and symptoms) reduces the counts of terms. This is very important to consider when reviewing adverse event profiles. The profile obtained when both diagnosis and signs and symptoms have been coded will appear very different than the profile obtained when only a diagnosis has been coded. An organization s coding conventions should always be considered whenever the data from other databases (e.g., co-developing or co-marketing partners, regulators) are used and/or compared. 2.4 Impact of MedDRA s Characteristics on Data Retrieval and Presentation The structure, rules and conventions of MedDRA are detailed in the MedDRA Introductory Guide. The following characteristics of MedDRA need to be kept in mind for data retrieval and presentation: Grouping Terms - HLGTs and HLTs The hierarchy of MedDRA, in particular the HLGT and HLT levels, should be viewed as an additional tool to aid in data retrieval and presentation, as it provides clinically relevant groupings of terms. Example: HLGT Cardiac arrhythmias HLT Cardiac conduction disorders HLT Rate and rhythm disorders NEC HLT Supraventricular arrhythmias HLT Ventricular arrhythmias and cardiac arrest However, the user should review the terms within the HLGT or HLT of interest to ensure that all terms are suited for the purpose of the output. Note in the example below that terms describing changes in blood pressure in both 5

9 directions are grouped under a common HLT. Example: HLT Vascular tests NEC (incl blood pressure) PT Blood pressure decreased PT Blood pressure increased PT Blood pressure PT Blood pressure abnormal This HLT also includes many other PTs for parameters such as pulmonary arterial pressure, vascular resistance, haemodynamic tests, etc. Clinically related PTs in MedDRA might be overlooked or not recognized as belonging together as they might exist in different locations within a single SOC. Example: HLGT Epidermal and dermal conditions HLT Bullous conditions PT Stevens-Johnson syndrome PT Toxic epidermal necrolysis HLT Exfoliative conditions PT Nikolsky s sign PT Dermatitis exfoliative generalised PT Dermatitis exfoliative PT Skin desquamation Hence, the overall frequency of a medical concept might be underestimated if the above points are not taken into consideration, possibly impacting the interpretation of the data. 2.5 Granularity Unique medical concepts (PTs) in MedDRA are considerably more specific (i.e., granular ) than terms on a comparable level of hierarchy in other terminologies. As a consequence of this specificity, related events that might have been represented by a single term in other terminologies might now be represented among more than one MedDRA PT. This can compromise signal detection. The following table illustrates how data coded to a single PT from another terminology may be expressed by several PTs in MedDRA. OTHER TERMINOLOGY PREFERRED TERMS # SUBJ. MEDDRA VERSION7.1 PREFERRED TERMS Infection 12 Upper respiratory tract infection Nasopharyngitis Infection # SUBJ

10 Lower respiratory tract infection Skin infection Abdominal pain 9 Abdominal pain Abdominal pain upper Abdominal tenderness Accidental injury 4 Injury Skin laceration Joint sprain Back injury Multi-axiality MedDRA is a multi-axial terminology, which means that a PT may be assigned to more than SOC. Multi-axiality allows terms to be grouped in different ways (e.g., by etiology or body system/site). Each PT is assigned to one primary SOC; assignments of that PT to other SOCs are considered secondary. Assignment of a single primary SOC prevents multiple counting. MedDRA users should be aware of primary SOC assignment rules that will affect the way data are distributed across the terminology. Because MedDRA placement rules allow for terms related to a particular medical condition to reside in more than one SOC, users should be familiar with the general content and structure of all MedDRA SOCs to ensure that data are not overlooked. Example: All terms reflecting congenital events are primary to the SOC Congenital, familial and genetic disorders. Example: The primary assignment for PT Enterocolitis infectious is SOC Infections and infestations (with a secondary assignment to SOC Gastrointestinal disorders) whereas the primary assignment for PT Enterocolitis is SOC Gastrointestinal disorders. Clinically related PTs in MedDRA could be overlooked or not recognized as belonging together because they might be distributed among two or more SOCs. Example: PT Thrombocytopenia is in SOC Blood and lymphatic system disorders PT Platelet count decreased is in SOC Investigations MedDRA s 26 SOCs address anatomical locations and etiology, as well as purposes or other concepts; therefore, data might reside in SOCs that are not anticipated by the user. Thus, the impact of multi-axiality on frequencies of the medical condition of interest should be considered. Example: PT Post procedural haemorrhage has the primary SOC assignment of SOC Injury, poisoning and procedural complications PT Chest pain has the primary SOC assignment of SOC General disorders and administration site conditions 7

11 Example: For hepatic abnormality, SOC Investigations, should be searched (in addition to SOC Hepatobiliary disorders) to identify related laboratory test terms. Furthermore, SOC Surgical and medical procedures should be searched for related terms such as PT Liver transplant. All possible secondary SOC assignments for any given concept may not exist in MedDRA. However, MedDRA is an evolving terminology and new or revised SOC assignments can be created in the future as a result of the change request process. Users should also be aware that the following three SOCs do not have multiaxial assignments for any of their terms (i.e., terms assigned to these SOCs do not appear in any other SOC): SOC Investigations SOC Surgical and medical procedures SOC Social circumstances When designing retrieval strategies, one should not overlook terms in these SOCs. Laboratory test results are not linked via multi-axiality to a corresponding medical condition. For example, PT Blood glucose increased is in SOC Investigations (its only SOC assignment) but PT Hyperglycaemia is in SOC Metabolism and nutrition disorders and has no link to SOC Investigations. Tables or other views of the data need to take into account the impact of SOC Investigations. As illustrated in the table below, multiple MedDRA terms might be used to code very similar medical conditions and might be included in a disorder SOC while its associated laboratory finding is displayed in SOC Investigations. Reported Event (% subjects) Hyperglycaemia (4.1) Increased blood sugar (2.7) Glucose increased (2.2) Blood glucose high (1.0) Increasing glucoses (0.5) OTHER TERMINOLOGY MedDRA version 7.1 Body System/SOC PT SOC (% subjects) (% subjects) (% subjects) Metabolism & Hyperglycaemia nutritional (4.1) disorders (4.1) Coded Term (% subjects) Hyperglycemia (10.5) Metabolism & nutritional disorders (10.5) Blood glucose increased (6.4) Investigations (6.4) 2.7 Special Search Categories As with other terminologies, some clinical conditions and syndromes cannot be fully represented in one MedDRA SOC. For example, anaphylaxis is manifested in various parts of the body at the same time and terms for related signs and symptoms are spread over more than one SOC; they are not completely grouped by one HLT or HLGT. MedDRA provides Special Search 8

12 Categories (SSCs) comprised entirely of PTs, which group terms relevant to a particular condition together across SOCs. 2.8 Standardized MedDRA Queries 4 Standardised MedDRA Queries (SMQs) are a joint effort of the Council for International Organizations of Medical Sciences (CIOMS) SMQ Working Group and ICH (MSSO/JMO). SMQs are groupings of terms from one or more SOCs that relate to a defined medical condition or area of interest. The terms included could relate to signs, symptoms, diagnoses, syndromes, physical findings, laboratory and other physiologic test data, etc., that are associated with the medical condition or area of interest. SMQs differ from SSCs in several ways: SMQs can contain grouping terms (HLTs and HLGTs) as well as PTs, whereas SSCs only contain PTs Development of SMQs is focused on highly relevant drug safety topics SMQs can have usage options such as narrow and broad subsearches, hierarchical relationships between related SMQs and algorithmic design 2.9 MedDRA Versioning The MedDRA terminology is updated twice per year. It is important to consider the impact of the changes (e.g., new terms or changes in primary SOC assignment) on retrieval and presentation strategies. Users should read the documentation provided with each MedDRA release, especially the What s New document that lists the changes in detail. When planning or performing data retrieval and presentation, the version of MedDRA used should be documented. The terms used for queries should be in the same MedDRA version as the data being queried. For example, new terms might have been included in a query built on MedDRA version 7.1 that might not be represented in stored data coded in MedDRA version 5.0; this could lead to search results that are incomplete. On the other hand, a search built on an earlier MedDRA version (e.g., from a closed study), might not detect all of the relevant data in an integrated safety summary (ISS) coded in a later version of MedDRA. Any queries stored in an organization s system should be updated to the appropriate version of MedDRA prior to use on new data. 4 Contains an introduction to SMQs but the full publication is available only as a paper copy. Contains the minutes of the meetings. Publication = SMQs: Development and Rational use of Standardised MedDRA Queries (SMQs) 9

13 3 QUERIES and RETRIEVAL 3.1 General Principles: Data retrieval is performed for summary and analysis of clinical trial data, pharmacovigilance, medical information queries and for a number of other purposes. The search strategies, methods and tools applied to retrieve the data might be different depending on the intended use of the output. The user should be aware of particular database characteristics, organizationspecific data entry conventions, data sources, and the size of the database. In addition, archives of previously used searches might be available, particularly for pharmacovigilance purposes; with updating, these may be suitable for reuse. The user should be aware of the version of MedDRA used in coding all data. During the course of data retrieval, it is important that the user develop a clear understanding of the important safety issues as early in the search process as possible. Information from pre-clinical trials, the ADR/AE profile from clinical trials, knowledge of ADR/AE profiles of similar products, and regulatory queries can be useful in identifying areas of possible focus. Understanding some of these issues might affect the strategy for aggregation of search terms. Capturing related adverse events into categories can be difficult; a search that is defined with parameters that are too narrow might exclude events of potential relevance, whereas parameters that are too broad might make it difficult to identify a trend or signal. The grouping of terms that describes a potential effect, whether or not it can be regarded as a syndrome, requires medical judgment and the results of the analysis should be carefully interpreted. For complex queries, it is advisable to create a data analysis plan. In presenting adverse events, it is important to display and to group related events (i.e., events that represent the same condition of interest) so that the true occurrence rate of an event is not obscured. Search strategies should be documented and retrieved data should be adjudicated. The following are examples of the types of searches for which these principles might apply: Overview of safety profile in a summary report, Periodic Safety Update Report (PSUR), ISS, etc. Comparison of the frequency of ADR/AE (reporting rates for spontaneous reports or incidence for studies) Analysis of a specific safety concern Identification of patient subpopulations at risk 10

14 3.2 Overall Presentation of Safety Profiles The aim of an overall presentation of the safety profile is to highlight the distribution of ADR/AEs and to identify areas where more in depth analysis should be conducted. The data should be presented in a way that allows ready recognition of patterns of terms potentially associated with relevant medical conditions. Historically, the standard approach has been to present data by "Body System" or "System Organ Class" and Preferred Term corresponding to SOCs and PTs in MedDRA. However, due to the unique characteristics of MedDRA previously described (granularity, multi-axiality, etc.), this type of presentation alone might not optimally represent the frequency of events and can even be misleading. For example, if a number of reports describe a similar medical condition, they could be represented under various specific PTs, thereby diluting the signal Overview by Primary System Organ Class As a first look, one should display all data. This assures that all events will be seen and the overview might be useful in identifying clusters, perhaps in an HLT or HLGT. For a small data set, this might be all that is required. Objectives: To display all the data in the entire MedDRA structure To include all events (as this approach is all-inclusive, no events are omitted) It is recommended that this overview be undertaken as the first step in data retrieval and for planning further analyses. Method: The primary SOC view of the data including HLGTs, HLTs, and PTs can be used for standard tables (clinical trial and post-marketing data) and cumulative summaries (post-marketing data). Line listings (both clinical and post-marketing data) can also be displayed by primary SOC and PT. It might be sufficient to use the primary SOC and PT display only for small data sets, but it might be preferable to display data by SOC as well as by grouping terms (HLGTs and HLTs) and PTs for more complex data. The Internationally Agreed Order of SOCs was developed to facilitate consistency irrespective of language or alphabet. The order of the SOCs was based upon the relative importance of each SOC in ADR/AE reports. Whenever suitable, organizations should consider the use of Internationally Agreed Order of SOCs (see the MedDRA Introductory Guide and MedDRA ASCII files) rather than alphabetical order or frequency. However, organizations exchanging data should discuss and agree on the order of SOCs when preparing data for presentation. 11

15 MedDRA 7.1 English Alphabetical Order Blood and lymphatic system disorders Cardiac disorders Congenital, familial and genetic disorders Ear and labyrinth disorders Endocrine disorders Eye disorders Gastrointestinal disorders General disorders and administration site conditions Hepatobiliary disorders Immune system disorders Infections and infestations Injury, poisoning and procedural complications Investigations Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nervous system disorders Pregnancy, puerperium and perinatal conditions Psychiatric disorders Renal and urinary disorders Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Social circumstances Surgical and medical procedures Vascular disorders MedDRA 7.1 Internationally Agreed Order Infections and infestations Neoplasms benign, malignant and unspecified (incl cysts and polyps) Blood and lymphatic system disorders Immune system disorders Endocrine disorders Metabolism and nutrition disorders Psychiatric disorders Nervous system disorders Eye disorders Ear and labyrinth disorders Cardiac disorders Vascular disorders Respiratory, thoracic and mediastinal disorders Gastrointestinal disorders Hepatobiliary disorders Skin and subcutaneous tissue disorders Musculoskeletal and connective tissue disorders Renal and urinary disorders Pregnancy, puerperium and perinatal conditions Reproductive system and breast disorders Congenital, familial and genetic disorders General disorders and administration site conditions Investigations Injury, poisoning and procedural complications Surgical and medical procedures Social circumstances Graphical display might facilitate understanding by the viewer. This can include histograms, bar charts, pie charts etc. Benefits: Provides a broad overview of the distribution of data and helps to identify areas of special interest that might call for more in-depth analysis. Grouping terms help to aggregate related PTs to facilitate the identification of medical conditions of interest. An individual PT will be displayed only once, preventing over counting of terms. The primary SOC overview might be the only form of analysis appropriate for a small data set. In-depth analysis will require medical expertise in order to define terms that should be aggregated. Limitations: Because it is based on primary PT-to-SOC assignment, there might be incomplete groupings of terms that relate to a particular medical condition/syndrome because they might be distributed among different SOCs. Due to certain MedDRA rules, events might not be found where the user expects 12

16 them to be. Another potential limitation is a very lengthy output Focused Searches Objectives: In certain situations such as those listed below [Note: this list is not all inclusive], users might wish to design a specific search in addition to the Overview by Primary System Organ Class (section 3.2.1). Further examination of clusters seen in Primary SOC output Previously identified safety concerns (e.g., known class effects, results from toxicology and animal studies, etc.) Monitoring events of special interest Responding to regulatory and other queries It is recommended that the initial focused search augment the Overview by Primary System Organ Class (section 3.2.1) by exploiting the secondary SOC assignments available in MedDRA. Method: Display the SOC or the HLGT/HLT relevant to the search with all the primary and secondary terms. Using this method, displaying more than one SOC leads to double counting of terms. If applicable, link relevant PTs from the three non-multi-axial SOCs (i.e., SOC Investigations, SOC Surgical and medical procedures, and SOC Social circumstances). Benefits: The multi-axial links enhance the meaningfulness of the grouping terms. In other words, this method overcomes the limitations described under 2.6. Limitations: Covers only conditions that are confined under one SOC or HLGT/HLT. For medical conditions that involve terms in more than one SOC, users should consider using an SMQ. 13

17 4 Appendices: 4.1 Current members of the ICH Points to Consider working group: Rapporteur: Reinhard Fescharek Japan: Ministry of Health, Labour and Welfare: Tatsuo Kishi Kenichi Tamiya Manabu Yamamoto Japan Pharmaceutical Manufactures Association Takayoshi Ichikawa Yo Tanaka Japanese Maintenance Organization Reiji Tezuka Yasuo Sakurai Akemi Ishikawa European Union: Commission of the European Communities Dolores Montero Carmen Kreft-Jais European Federation of Pharmaceutical Industries Associations Reinhard Fescharek Christina Winter Canada: Health Canada Bill Wilson United States: US Food and Drug Administration John (Jake) Kelsey Toni Piazza-Hepp Pharmaceutical Research and Manufacturers of America Susan M. Lorenski JoAnn Medbery MedDRA MSSO Patricia Mozzicato 14

18 4.2 Past members/affiliations of the ICH Points to Consider working group: Japan: Ministry of Health, Labour and Welfare Tamaki Fushimi Kazuhiro Kemmotsu Chie Kojima Emiko Kondo Kemji Kuramochi Kaori Nomura Takashi Yasukawa Japan Pharmaceutical Manufacturers Association Akemi Ishikawa Satoru Mori Yasuo Sakurai Kunikazu Yokoi Japanese Maintenance Organization Yuki Tada Canada: Health Canada Heather Morrison European Union: European Federation of Pharmaceutical Industries Associations Barry Hammond past Rapporteur United States: US Food and Drug Administration Miles Braun Brad Leissa Andrea Feight Pharmaceutical Research and Manufacturers of America David Goldsmith Sidney Kahn Margaret M. Westland past Rapporteur MedDRA MSSO JoAnn Medbery 15

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release 1.4 Based on MedDRA Version 10.1 ICH-Endorsed Guide for MedDRA Users on Data Output 12 September 2007 Copyright ICH Secretariat (c/o IFPMA)

More information

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.7 Based on MedDRA Version 17.0 1 March 2014 1 The following is a listing of changes made between

More information

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.6 Based on MedDRA Version 16.1 1 October 2013 Disclaimer and Copyright Notice This

More information

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.14 Based on MedDRA Version 20.1 1 September 2017 Disclaimer and Copyright Notice

More information

MedDRA Overview A Standardized Terminology

MedDRA Overview A Standardized Terminology MedDRA Overview A Standardized Terminology Patrick Revelle Director, MedDRA MSSO 6 May 2010 MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations

More information

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.6 Based on MedDRA Version 16.1 1 October 2013 1 The following is a listing of changes made

More information

MedDRA Basic Concept

MedDRA Basic Concept MedDRA Basic Concept Pansie Zhang MSD R&D (China) Co., Ltd 23Apr2015 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not

More information

What s New MedDRA Version 13.1

What s New MedDRA Version 13.1 What s New MedDRA Version 13.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered

More information

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Judy Harrison Chief Medical Officer MedDRA MSSO 22 October 2013 MedDRA Data

More information

What s New MedDRA Version March

What s New MedDRA Version March C What s New MedDRA Version 21.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is registered by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and

More information

What s New MedDRA Version March

What s New MedDRA Version March c What s New MedDRA Version 20.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

Introduction to MedDRA

Introduction to MedDRA Introduction to MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration

More information

Data Analysis and Query Building with MedDRA

Data Analysis and Query Building with MedDRA Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The

More information

What s New MedDRA Version MSSO-DI March 2016

What s New MedDRA Version MSSO-DI March 2016 c What s New MedDRA Version 19.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

Data retrieval using the new SMQ Medication Errors

Data retrieval using the new SMQ Medication Errors Data retrieval using the new SMQ Medication Errors Christina Winter Medical Director Safety Evaluation and Risk Management, GSK Information Day on Medication Errors 20 October 2016 London, UK Disclaimer

More information

What s New MedDRA Version 15.1

What s New MedDRA Version 15.1 What s New MedDRA Version 15.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

What s New MedDRA Version 18.0

What s New MedDRA Version 18.0 What s New MedDRA Version 18.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

What s New MedDRA Version 14.0

What s New MedDRA Version 14.0 What s New MedDRA Version 14.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered

More information

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr. Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI 23-24 EKİM 2003 Dr. Tomás Moraleda Agenda 1. What is MedDRA? 2. Conditions before MedDRA 3. MedDRA

More information

Perspective: E2B transmission

Perspective: E2B transmission Perspective: E2B transmission I2B(M) Information about the safety report itself A.1 Report identification A.2 Primary source of information A.3.1 Who sends the information A.3.2 Who receives it Case information

More information

Safety Data Analysis and Query Creation with MedDRA

Safety Data Analysis and Query Creation with MedDRA Safety Data Analysis and Query Creation with MedDRA Anne Kehely & Eva Rump Eli Lilly/MSSO 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Insert your logo in this area then delete this text

More information

MedDRA Coding Quality: How to Avoid Common Pitfalls

MedDRA Coding Quality: How to Avoid Common Pitfalls MedDRA Coding Quality: How to Avoid Common Pitfalls Patricia Mozzicato, MD Chief Medical Officer MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides are those of

More information

Data Analysis and Query Building with MedDRA

Data Analysis and Query Building with MedDRA Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The

More information

Introductory Guide MedDRA Version 15.0

Introductory Guide MedDRA Version 15.0 Introductory Guide MedDRA Version 15.0 Acknowledgements Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory

More information

Introductory Guide MedDRA Version 14.0

Introductory Guide MedDRA Version 14.0 Introductory Guide MedDRA Version 14.0 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory

More information

MedDRA - International standard for coding safety information. The Golden Triangle

MedDRA - International standard for coding safety information. The Golden Triangle MedDRA - International standard for coding safety information International Pharmacovigilance Conference Moscow, Russia 10 October 2018 Anna Zhao-Wong, MD, PhD MedDRA MSSO The Golden Triangle (MedDRA)

More information

MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell

MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 14.0 Terminology Frequency

More information

Advanced MedDRA Coding

Advanced MedDRA Coding Advanced MedDRA Coding MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities

More information

Introductory Guide MedDRA Version 18.1

Introductory Guide MedDRA Version 18.1 Introductory Guide MedDRA Version 18.1 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory

More information

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes MedDRA 13.0 Review MedDRA Version Changes General Remarks MedDRA Version 13.0 Specific Changes Version 13.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 13.0 Terminology Frequency

More information

Proposed MedDRA Version 17.0 Complex Changes (July 2013)

Proposed MedDRA Version 17.0 Complex Changes (July 2013) Proposed MedDRA Version 17.0 Complex Changes (July 2013) MedDRA User Submitted Requests: 1. Add a new HLT Exserohilum infections to HLGT Fungal infectious disorders Submitter rationale: Adding this HLT

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A

More information

What Medical Writers Need to Know About MedDRA

What Medical Writers Need to Know About MedDRA What Medical Writers Need to Know About MedDRA Expert Seminar Series Session 2 40 th EMWA Conference, Dublin 6 May 2015 Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO MedDRA was developed under

More information

MedDRA Safety Data Analysis and SMQs

MedDRA Safety Data Analysis and SMQs MedDRA Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration

More information

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations Judy Harrison, M.D. Chief Medical Officer MedDRA MSSO Information Day on Medication Errors 20 October 2016 London,

More information

MedDRA: Safety Data Analysis and SMQs

MedDRA: Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

More information

MedDRA: Safety Data Analysis and SMQs

MedDRA: Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

More information

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know MedDRA 10.1 Review MedDRA Version Changes General Remarks Terminology Files: What you need to know MedDRA Version 10.1 Specific Changes Version 10.1 Changes Overview Changes in a Nutshell Changes Highlights

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A

More information

Coding with MedDRA 3/6/2019

Coding with MedDRA 3/6/2019 Coding with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA

More information

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania. WHO-ART Magnus Wallberg November 24 th 2009 Dar Es Salaam, Tanzania magnus.wallberg@who-umc.org WHO-ART (WHO-Adverse Reaction Terminology) The need for a medical terminology dyspnoea? tinnitus ARDS fever

More information

MedDRA Term Selection: Latest activities of the Points to Consider Working Group

MedDRA Term Selection: Latest activities of the Points to Consider Working Group MedDRA Term Selection: Latest activities of the Points to Consider Working Group Patrick Revelle MedDRA MSSO 23 May 2013 Overview The new EU pharmacovigilance legislation broadened the definition of an

More information

Best practices in VeDDRA coding

Best practices in VeDDRA coding Best practices in VeDDRA coding 27 November 2013 Presented by: Giles Davis Chair of PhVWP-V VeDDRA sub-group An agency of the European Union Veterinary Dictionary for Drug Related Affairs SOC = System

More information

Use of MedDRA in Special Situations

Use of MedDRA in Special Situations Use of MedDRA in Special Situations Patrick Revelle MedDRA MSSO 13 March 2012 Overview Existing terms in MedDRA for off-label use, abuse, misuse, overdose, and medication errors Current coding recommendations

More information

Coding with MedDRA 4/22/2015

Coding with MedDRA 4/22/2015 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities

More information

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0) SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant

More information

Adverse Event Terminology and Coding Working Group

Adverse Event Terminology and Coding Working Group Adverse Event Terminology and Coding Working Group March 2018 Working Group Chair: H. Ishikawa Office of Standards and Guidelines Development Pharmaceuticals and Medical Devices Agency Overview of IMDRF

More information

ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT)

ClinicalTrials.gov Basic Results Data Element Definitions (DRAFT) ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT) January 9, 2009 * Required by ClinicalTrials.gov [*] Conditionally required by ClinicalTrials.gov (FDAAA) May be required to comply with

More information

A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database

A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

Coding with MedDRA 3/2/2017

Coding with MedDRA 3/2/2017 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities

More information

ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy

ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Background Regulatory authorities

More information

MedDRA Coding and Versioning

MedDRA Coding and Versioning MedDRA Coding and Versioning 4th ANNUAL INNOVATIONS IN CLINICAL DATA MANAGEMENT Alexandria, VA. 27-28 October 2016 Anna Zhao-Wong, MD, PhD Deputy Director of MedDRA MSSO anna.zhao-wong@meddra.org Agenda

More information

Search for studies: ClinicalTrials.gov Identifier: NCT

Search for studies: ClinicalTrials.gov Identifier: NCT ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.10 Based on MedDRA Version 11.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical and Social History

More information

Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH

Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration

More information

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration

More information

Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2012:

Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2012: Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2012: VACCINE-ASSOCIATED SUSPECTED ADVERSE REACTIONS REPORTED VIA THE YELLOW CARD SCHEME DURING 2011 September 2012 CONTENTS

More information

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1 Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy

More information

PRAC recommendations on signals

PRAC recommendations on signals 3 October 2013 EMA/PRAC/550442/2013 Pharmacovigilance Risk Assessment Committee Adopted at the PRAC meeting of 2-5 September 2013 This document provides an overview of the recommendations adopted by the

More information

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.12 Based on MedDRA Version 12.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical

More information

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.8 Based on MedDRA Version 10.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Coding with MedDRA 1

Coding with MedDRA 1 Coding with Coding with MedDRA 1 4/3/2015 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals

More information

Terminologies for recording of ADR:s

Terminologies for recording of ADR:s Terminologies for recording of ADR:s 1 Adverse reaction terms? Dizziness SOB. feeling hot.? dyspnoea lightheadedness.? breath shortness. evidence of VEBS on 2 ECG Concepts Terminology collection of accepted

More information

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With

More information

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309

More information

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Frequently Asked Questions

Frequently Asked Questions Welcome to the European MedDRA Users Group Webinar on Update on Medication errors The session will be chaired by Ian Slack Liz Thomas from the MSSO will provide technical support Asking Questions Using

More information

EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS

EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS Last updated (Rev.): 21 December 2007 Publication Date: 14 March 2007 NOTES

More information

Assurance Engagements Other than Audits or Review of Historical Financial Statements

Assurance Engagements Other than Audits or Review of Historical Financial Statements Issued December 2007 International Standard on Assurance Engagements Assurance Engagements Other than Audits or Review of Historical Financial Statements The Malaysian Institute Of Certified Public Accountants

More information

DIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE:

DIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE: DIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE: THE BASICS Preferred Clinical Services for Leading Age Florida August 26-27, 2015 WHAT IS ICD-10-CM? International Classification of Diseases, 10 th Revision,

More information

Optum360 Learning: Detailed Instruction for Appropriate ICD-10-CM Coding

Optum360 Learning: Detailed Instruction for Appropriate ICD-10-CM Coding Optum360 Learning: Detailed Instruction for Appropriate Coding An educational guide to the structure, conventions, and guidelines of coding 2017 Contents Section 1: Introduction...1 Documentation...7 Documentation

More information

1.1. An overview of reports on sitagliptin

1.1. An overview of reports on sitagliptin 1.1. An overview of reports on Introduction Sitagliptin (Januvia ) was registered for the European marked on March 21 st 27 with the Netherlands as rapporteur. It is indicated as treatment of for patients

More information

Coding with MedDRA. Course Overview

Coding with MedDRA. Course Overview Coding with MedDRA MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Course Overview MedDRA background MedDRA s structure, scope,

More information

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management

More information

PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin)

PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin) ONC.000-092-861.10.0 PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG (goserelin) Name of the medicinal product Zoladex LA 10.8mg depot Qualitative and quantitative composition Goserelin acetate (equivalent to 10.8

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.13 Based on MedDRA Version 20.0 1 March 2017 Disclaimer and Copyright Notice This document is protected by copyright

More information

How can Natural Language Processing help MedDRA coding? April Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics

How can Natural Language Processing help MedDRA coding? April Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics How can Natural Language Processing help MedDRA coding? April 16 2018 Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics Summary About NLP and NLP in life sciences Uses of NLP with MedDRA

More information

Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2013:

Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2013: Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2013: VACCINE-ASSOCIATED SUSPECTED ADVERSE REACTIONS REPORTED VIA THE YELLOW CARD SCHEME DURING 2012/13 September 2013

More information

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016 Session 2 Data analysis based on overview of EudraVigilance data Victoria Newbould, EMA, EU Medication-errors workshop London, 20 October 2016 An agency of the European Union Acknowledgement Steven Le

More information

Implemented MedDRA Version 22.0 Complex Changes (October 2018)

Implemented MedDRA Version 22.0 Complex Changes (October 2018) Implemented MedDRA Version 22.0 Complex Changes (October 2018) MedDRA User Proposed Requests: 1. Move HLT Cardiac disorders NEC from HLGT Cardiac disorder signs and symptoms to new HLGT Cardiac disorders

More information

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use Frequently Asked Questions Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions The Q4B Expert Working Group developed a set of frequently asked questions to help users

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.8 Based on MedDRA Version 17.1 1 September 2014 Disclaimer and Copyright Notice This document is protected by copyright

More information

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of

More information

Coding with MedDRA 1

Coding with MedDRA 1 Coding with Coding with MedDRA 1 3/9/2017 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals

More information

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013 MedDRA Coding/ AE Log Item 1 Refresher ASPIRE Protocol Team Meeting February 10, 2013 MedDRA Coding Overview MedDRA: standardized dictionary of medical terminology Results from ICH initiative to standardize

More information

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013 ClinicalTrials.gov ID: NCT00168454 Study Identification Unique Protocol ID: 191622-077 Brief Title: A

More information

A chapter by chapter look at the ICD-10-CM code set Coding Tip Sheet

A chapter by chapter look at the ICD-10-CM code set Coding Tip Sheet Coding Tip Sheet Chapter 1 - Certain Infectious and Parasitic Diseases Terminology changes: The term Sepsis (ICD-10-CM) has replaced the term Septicemia (ICD-9-CM) Urosepsis is a nonspecific term and is

More information

"ICD-10 For Clinical Staff" February 21, 2014 by Paula Digby, CPC, CCS, CPCI, AHIMA Approved ICD-10-CM/PCS Instructor. Disclaimer

ICD-10 For Clinical Staff February 21, 2014 by Paula Digby, CPC, CCS, CPCI, AHIMA Approved ICD-10-CM/PCS Instructor. Disclaimer Slide 1 1 Slide 2 Disclaimer The information contained in this presentation is provided to assist the attendee in understanding the reimbursement process. It is intended to assist healthcare providers

More information

INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION CONTENTS

INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION CONTENTS INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION (Effective for assurance reports dated on or after January 1,

More information

15 May 2017 Exposure Draft. Response Due Date 23 June Exposure Draft

15 May 2017 Exposure Draft. Response Due Date 23 June Exposure Draft 15 May 2017 Exposure Draft Response Due Date 23 June 2017 Exposure Draft Proposed Application Material Relating to: (a) Professional Skepticism Linkage with the Fundamental Principles; and (b) Professional

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.4 Based on MedDRA Version 15.1 1 October 2012 Disclaimer and Copyright Notice This document is protected by copyright

More information

0BCore Safety Profile

0BCore Safety Profile 0BCore Safety Profile Active substance: Somatropin Pharmaceutical form(s)/strength: Powder and solvent for solution for injection, 4mg/ml, 5 mg/ml and 10 mg/ml P-RMS: FR/H/PSUR/0059/001 Date of FAR: 25.02.2013

More information

AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)

AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014) AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION (Moscow, 23 December 2014) Member States of the Eurasian Economic Union, hereinafter referred

More information

A Global Patient Registry for Human Avian Influenza

A Global Patient Registry for Human Avian Influenza A Global Patient Registry for Human Avian Influenza Understanding Clinical Presentation, Treatment Outcomes, and Survival Introduction September, 2008 Human Avian Influenza represents a major concern for

More information

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 25, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

HI-1051: Certified Professional Coder Preparation Course

HI-1051: Certified Professional Coder Preparation Course Course Code/Title: HI-1051: Certified Professional Coder Preparation Course Course Hours: 320 Duration (wks): 16 weeks Chapter 1 The Business of Medicine Coding as a Profession The Difference between Hospital

More information

Basis for Conclusions: ISA 230 (Redrafted), Audit Documentation

Basis for Conclusions: ISA 230 (Redrafted), Audit Documentation Basis for Conclusions: ISA 230 (Redrafted), Audit Documentation Prepared by the Staff of the International Auditing and Assurance Standards Board December 2007 , AUDIT DOCUMENTATION This Basis for Conclusions

More information

Health informatics Digital imaging and communication in medicine (DICOM) including workflow and data management

Health informatics Digital imaging and communication in medicine (DICOM) including workflow and data management INTERNATIONAL STANDARD ISO 12052 Second edition 2017-08 Health informatics Digital imaging and communication in medicine (DICOM) including workflow and data management Informatique de santé Imagerie numérique

More information